Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer.
Sassu CM, Palaia I, Boccia SM, Caruso G, Perniola G, Tomao F, Di Donato V, Musella A, Muzii L. Sassu CM, et al. Int J Mol Sci. 2021 Dec 20;22(24):13650. doi: 10.3390/ijms222413650. Int J Mol Sci. 2021. PMID: 34948446 Free PMC article. Review.
Fertility preservation in ovarian tumours.
Tomao F, Di Pinto A, Sassu CM, Bardhi E, Di Donato V, Muzii L, Petrella MC, Peccatori FA, Panici PB. Tomao F, et al. Among authors: sassu cm. Ecancermedicalscience. 2018 Dec 6;12:885. doi: 10.3332/ecancer.2018.885. eCollection 2018. Ecancermedicalscience. 2018. PMID: 30679952 Free PMC article. Review.
Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
Tomao F, Bardhi E, Di Pinto A, Sassu CM, Biagioli E, Petrella MC, Palaia I, Muzii L, Colombo N, Panici PB. Tomao F, et al. Among authors: sassu cm. Cancer Treat Rev. 2019 Nov;80:101909. doi: 10.1016/j.ctrv.2019.101909. Epub 2019 Oct 9. Cancer Treat Rev. 2019. PMID: 31629204 Review.
First-Line Treatment  with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research.
Tomao F, Boccia SM, Sassu CM, Chirra M, Palaia I, Petrella MC, Di Donato V, Colombo N, Benedetti Panici P. Tomao F, et al. Among authors: sassu cm. Cancer Manag Res. 2020 Jul 7;12:5479-5489. doi: 10.2147/CMAR.S194874. eCollection 2020. Cancer Manag Res. 2020. PMID: 32765062 Free PMC article. Review.
Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.
Musella A, Bardhi E, Marchetti C, Vertechy L, Santangelo G, Sassu C, Tomao F, Rech F, D'Amelio R, Monti M, Palaia I, Muzii L, Benedetti Panici P. Musella A, et al. Cancer Treat Rev. 2018 May;66:7-14. doi: 10.1016/j.ctrv.2018.03.004. Epub 2018 Mar 23. Cancer Treat Rev. 2018. PMID: 29605737 Review.
Recurrent mantle cell lymphoma in the uterine cervix: a case report.
Santangelo G, Palaia I, Perniola G, Di Pinto A, Musella A, Tomao F, Fischetti M, Sassu C, Piccioni M, Di Donato V, Benedetti Panici P. Santangelo G, et al. J Med Case Rep. 2020 Sep 2;14(1):138. doi: 10.1186/s13256-020-02487-6. J Med Case Rep. 2020. PMID: 32873335 Free PMC article.
17 results